In this mechanistic framework, the 25 mg peak window is the PK region surrounding peak concentration generated by a 25 mg systemic input magnitude. The peak window basics framework describes this region around the maximum, while the peak curve represents the rise, maximum, and subsequent decline of sildenafil concentration. The 25 mg Tmax is the timing coordinate of maximum concentration for that input profile. The Tmax definition identifies the coordinate itself, while Tmax vs onset distinguishes PK timing from biological onset and Cmax vs Tmax separates peak magnitude from peak timing. The 25 mg absorption rate describes the mechanistic rate at which systemic input develops, with absorption rate and absorption mechanism describing complementary aspects of input. Upstream gastric emptying impact and intestinal uptake influence delivery and uptake, while the first-pass effect can reduce parent sildenafil before systemic appearance. The resulting bioavailability link connects these processes to systemic exposure.
The 25 mg profile is a concentration-time construct rather than a clinical dosing framework. After absorption and presystemic processing, systemic sildenafil enters a distribution phase represented by the distribution phase. The concentration then reflects the balance between systemic input and removal, producing a maximum that defines the 25 mg Tmax and the surrounding 25 mg peak window. Dose-related PK interpretation can be framed through the dose PK relationship, which relates input magnitude to exposure, while dose absorption limit describes conceptual constraints on absorption. The dose response curve belongs to a downstream exposure-response framework and does not redefine the peak window. Food-associated variables such as fatty food impact and light meal impact can alter upstream PK behavior, while alcohol impact on peak represents another potential modifier of peak-related concentration-time behavior. These modifiers may affect the shape, magnitude, or timing of the 25 mg profile without changing the underlying definitions.
The observed 25 mg peak window can also differ across modeled profiles because metabolic processes and biological variability influence systemic exposure. Enzyme inhibitors impact and enzyme inducers impact describe metabolic modifiers that can alter the amount or persistence of parent sildenafil. Interindividual variation and genetic variability provide conceptual explanations for differences in absorption, metabolism, and concentration-time behavior among individuals. The resulting timeline remains connected: a 25 mg input establishes an input magnitude; absorption determines how systemic input forms; first-pass processes modify the parent fraction reaching circulation; distribution shapes subsequent concentrations; Tmax identifies the maximum's timing; and the peak window describes the surrounding PK region. The 25 mg absorption rate therefore concerns systemic input formation, not therapeutic interpretation. Likewise, 25 mg Tmax describes timing, not an administration recommendation. This terminology keeps the analysis neutral, mechanistic, and descriptive while treating 25 mg solely as a PK input magnitude.
The 25 mg peak window describes the PK region surrounding the maximum concentration generated by a sildenafil profile modeled with a 25 mg input magnitude. The peak window basics framework establishes the temporal concept, while the peak curve displays the concentration rise, maximum, and decline. The 25 mg Tmax identifies the timing coordinate of the maximum within that curve. Tmax definition describes this coordinate, while Cmax vs Tmax distinguishes concentration magnitude from timing. The rising portion depends on the absorption rate and the absorption mechanism. Gastric emptying impact can influence delivery to intestinal sites, and intestinal uptake establishes the absorbed input available for subsequent processing. The first-pass effect can reduce parent drug before systemic circulation, affecting the profile from which the peak is observed.
The 25 mg peak window is a descriptive PK construct rather than a clinical timing instruction. The Tmax vs onset distinction separates the timing of maximum plasma concentration from the beginning of a biological response. The bioavailability link describes how presystemic processes contribute to the amount of parent sildenafil reaching systemic circulation. After systemic appearance, the distribution phase contributes to the evolving concentration-time curve. The maximum occurs when the net relationship between systemic input and removal produces the highest observed concentration. Consequently, the peak window depends on more than absorption alone. The peak curve integrates input, first-pass loss, distribution, and elimination, while the 25 mg Tmax identifies the temporal coordinate of its maximum. A change in any relevant upstream or downstream process can alter the location or shape of the peak window without changing the meaning of the underlying PK terms.
Because 25 mg is treated solely as an input magnitude, dose-related concepts are interpreted mechanistically rather than clinically. The dose PK relationship connects input magnitude with exposure, while dose comparison can describe differences among modeled input levels. Dose escalation impact describes how changing input magnitude may alter concentration-time behavior, without implying an administration recommendation. The dose response curve concerns downstream exposure-response relationships and is separate from the definition of the peak window. Food and metabolic variables can also alter the profile. Fatty food impact, light meal impact, and enzyme inhibitors impact illustrate modifier categories that may change systemic input or disposition. These effects can shift concentration magnitude, timing, or curve shape. The 25 mg peak window therefore remains an integrated property of the PK profile.
The 25 mg absorption rate describes the mechanistic rate at which systemic input develops from a 25 mg sildenafil input magnitude. It does not describe therapeutic intensity or clinical response. The absorption rate focuses on the temporal rate of input, while the absorption mechanism describes the processes that permit drug transfer into the systemic input pathway. Gastric emptying impact can influence when sildenafil reaches intestinal sites, while intestinal uptake establishes entry into the portal pathway. The first-pass effect can then reduce the amount of parent drug surviving to systemic circulation. The bioavailability link connects this presystemic loss with systemic availability. The resulting systemic input profile contributes to the rise toward the 25 mg concentration maximum, from which the 25 mg Tmax and peak window are defined.
The 25 mg Tmax is the PK timing coordinate of maximum concentration for the modeled 25 mg input. The Tmax definition identifies this time coordinate, while Cmax vs Tmax separates peak magnitude from peak timing. A faster or slower systemic input profile can influence Tmax, but Tmax is not determined by absorption rate alone. The distribution phase and later removal processes also contribute to the concentration-time shape. The Tmax vs onset distinction keeps the timing coordinate separate from pharmacodynamic onset. The peak window basics framework then places Tmax within a broader region surrounding maximum concentration. The peak curve provides the visual representation of these relationships. Thus, the 25 mg absorption rate contributes to peak formation, but the 25 mg peak window is an integrated outcome of input and disposition rather than a direct readout of absorption alone.
Dose-related PK concepts help contextualize the 25 mg input without turning the page into dosing guidance. The dose PK relationship describes how input magnitude relates to exposure, while dose absorption limit addresses conceptual limits on the formation of systemic input. The dose response curve represents a separate exposure-response construct. These relationships can influence the amount and shape of systemic exposure while preserving the definitions of absorption rate and Tmax. A 25 mg profile can therefore be compared mechanistically with other input magnitudes, but its peak window must still be interpreted from its own concentration-time curve. The key sequence remains absorption, first-pass processing, systemic appearance, distribution, maximum concentration, and peak window. Each stage contributes different information, and none should be treated as a direct proxy for the others. This separation preserves precise PK terminology.
| Component | Mechanistic Basis | Interpretation |
|---|---|---|
| 25 mg input | Defines the modeled sildenafil input magnitude used to construct the PK profile. | Provides the quantitative input condition without implying a clinical recommendation. |
| Absorption rate | Determines the temporal rate at which systemic input develops. | Shapes the rising portion of the concentration-time profile. |
| First-pass effect | Removes some parent sildenafil before systemic circulation. | Can alter the amount available for subsequent peak formation. |
| 25 mg Tmax | Marks the time coordinate of maximum concentration in the 25 mg profile. | Describes peak timing rather than peak magnitude. |
| Peak concentration | Represents the maximum observed concentration within the profile. | Describes the magnitude of the 25 mg concentration maximum. |
| Peak window | Defines the temporal region surrounding the concentration maximum. | Provides context for interpreting the timing and shape of the peak. |
The 25 mg peak window is produced by several connected PK layers. The absorption mechanism establishes how sildenafil enters the systemic input pathway, while the absorption rate describes the temporal pattern of that entry. Gastric emptying impact can alter when drug reaches intestinal absorption sites, and intestinal uptake establishes portal input. The first-pass effect can remove parent sildenafil before systemic appearance, with the bioavailability link describing the resulting relationship between absorbed input and systemic availability. Once systemic drug appears, the distribution phase contributes to concentration changes among compartments. These stages collectively shape the concentration-time curve from which the 25 mg Tmax and peak window are identified. The resulting peak is therefore an integrated PK property rather than a direct measure of any single upstream process.
The distinction between concentration magnitude and timing remains central to interpreting a 25 mg profile. Cmax vs Tmax separates maximum concentration from the time at which it occurs. The Tmax definition identifies the timing coordinate, while peak curve displays how the profile approaches and leaves its maximum. The peak window basics concept adds temporal context around the maximum, and Tmax vs onset distinguishes PK timing from biological onset. The peak effect physiology concept can be considered downstream, where exposure patterns are related conceptually to pharmacodynamic processes. None of these terms changes the definition of the 25 mg peak window. Rather, they describe different dimensions of the same PK profile and allow absorption, distribution, and peak timing to be analyzed without conflating separate mechanisms.
Modifiers can alter the 25 mg profile at different points in the PK sequence. Dose comparison can distinguish modeled input magnitudes, while dose PK relationship describes their relationship to exposure. Food-related concepts such as fatty food impact can affect upstream input conditions, while alcohol impact on peak represents another potential modifier of peak-related concentration behavior. Metabolic changes represented by enzyme inhibitors impact can alter parent-drug persistence or presystemic extraction. Enzyme inducers impact can alter metabolic capacity in the opposite mechanistic direction. The resulting concentration-time profile may show changes in peak magnitude, timing, or both. The 25 mg peak window should therefore be interpreted as an integrated output of input, extraction, distribution, and elimination rather than as a fixed temporal property independent of PK conditions.
Food-related modifiers can alter the upstream conditions that shape a 25 mg sildenafil concentration-time profile. Timing before meal and timing after meal describe temporal relationships between food and drug input without prescribing an administration schedule. Fatty food impact and light meal impact represent food-associated PK conditions that can influence gastrointestinal delivery or systemic input. These changes may propagate through absorption and alter the rising portion of the concentration-time curve. Gastric emptying impact provides one mechanistic pathway by which delivery timing can change. The resulting 25 mg Tmax may shift if the balance between input and disposition changes, while the peak concentration may also change. The peak curve therefore remains the appropriate integrated representation. Food-related modifiers should be interpreted as PK influences on the profile rather than as instructions concerning administration.
Alcohol can be considered another modifier of peak-related concentration-time behavior. The alcohol impact on peak concept encompasses possible changes involving gastrointestinal, metabolic, or systemic PK processes. Interaction-related mechanisms can be organized through drug interactions peak, while interaction summary provides a broader conceptual framework. Enzyme-related effects may involve enzyme inhibitors impact or enzyme inducers impact, potentially changing parent-drug availability or persistence. Such changes can influence the height of the 25 mg peak, the timing of its maximum, or the shape of the surrounding window. The direction and magnitude of an observed change depend on which PK process is affected and how that process interacts with absorption, distribution, and elimination. Consequently, a modified peak should be interpreted from the complete concentration-time profile rather than attributed automatically to a single mechanism.
Dose and timing variables can interact with food and metabolic processes in ways that alter the modeled 25 mg profile. The dose PK relationship describes how input magnitude relates to systemic exposure, while dose escalation impact describes changes associated with differing input magnitudes. Timing optimization and dose optimization are treated only as conceptual PK topics and not as recommendations. The resulting peak window depends on the complete sequence from absorption through systemic disposition. A modifier that delays input may influence Tmax, while one that changes systemic availability may primarily influence peak concentration. A metabolic modifier can affect both if it changes the balance between input and removal. The 25 mg peak window is therefore not a universal fixed interval independent of conditions. It is an emergent property of the modeled concentration-time profile for a defined input magnitude and set of PK processes.
| Modifier | PK/PD Link | 25 mg Peak Impact |
|---|---|---|
| Meal timing | Can modify the timing of gastrointestinal delivery and systemic input. | May shift the modeled 25 mg peak timing or alter peak magnitude. |
| Fatty food | Can influence gastrointestinal and absorption-related PK behavior. | May reshape the rising curve and alter the peak window. |
| Light meal | Represents another food-associated input condition. | Can modify the temporal pattern of the 25 mg concentration profile. |
| Alcohol | May influence gastrointestinal, metabolic, or systemic processes. | Can change peak magnitude, timing, or concentration-time shape. |
| Enzyme inhibition | Reduced metabolic activity can alter presystemic or systemic drug handling. | May increase or reshape systemic exposure and potentially shift the peak. |
| Enzyme induction | Increased metabolic capacity can increase drug loss through relevant pathways. | May reduce exposure and alter peak characteristics depending on pathway contribution. |
A modeled 25 mg peak window can differ between individuals because the biological processes determining input and disposition vary across subjects. Interindividual variation provides the broad framework for these differences, while genetic variability can contribute to variation in metabolic capacity. Age impact may influence physiological processes relevant to absorption and disposition, while hepatic function impact can affect metabolic handling. Renal function impact concerns later elimination processes and can therefore influence the overall concentration-time curve without directly defining absorption. Metabolic rate impact provides another mechanistic dimension. These factors can alter the magnitude or timing of systemic exposure. Consequently, a 25 mg input magnitude does not guarantee identical Cmax, Tmax, or peak-window characteristics across modeled individuals. The definitions remain constant even when the observed parameters vary.
Differences in absorption can affect the rising portion of the 25 mg concentration-time profile. Gastric emptying impact can alter the timing of intestinal delivery, while intestinal uptake determines how much drug enters the portal pathway. The first-pass effect can then modify the amount of parent sildenafil reaching systemic circulation. The bioavailability link connects these processes to systemic availability. Once drug appears systemically, the distribution phase contributes to concentration-time behavior. The resulting differences can influence the 25 mg Tmax, peak concentration, or the width and shape of the peak window. The Cmax vs Tmax distinction remains useful because magnitude and timing can vary independently. Thus, variability in a 25 mg profile should be interpreted as a combined result of multiple PK layers rather than assigned automatically to absorption alone.
Model-based analysis can organize these differences without treating any single individual profile as universal. Peak window modeling can represent variation in peak timing and shape, while population pharmacokinetics separates typical parameter behavior from between-subject variability. Clinical peak data can provide observed concentration-time measurements, and peak window summary can organize the temporal characteristics of those profiles. In this framework, 25 mg remains a defined input magnitude, while Cmax and Tmax are outputs of the modeled concentration-time system. Variation can arise from absorption, presystemic extraction, distribution, metabolism, or elimination. The peak window consequently represents a profile-specific region rather than an invariant interval. A mechanistic interpretation can describe these differences without assigning therapeutic meaning. This preserves the distinction between an input magnitude, a measured concentration maximum, its timing coordinate, and the broader temporal region surrounding the maximum.
The integrated 25 mg PK timeline begins with the input magnitude and proceeds through absorption, presystemic processing, systemic appearance, distribution, Tmax, and the peak window. The absorption mechanism describes how sildenafil enters the systemic input pathway, while absorption rate describes the temporal formation of that input. Gastric emptying impact can influence delivery to intestinal sites, and intestinal uptake establishes portal input. The first-pass effect can reduce parent drug before systemic circulation, with the bioavailability link describing the resulting systemic availability. The surviving drug then enters systemic circulation and undergoes processes represented by the distribution phase. The concentration rises toward its maximum, from which the 25 mg Tmax and peak window are defined. The peak curve integrates these stages visually.
The 25 mg Tmax is the timing coordinate at which the modeled concentration reaches its maximum, while the peak window describes the surrounding PK region. The Tmax definition establishes the timing concept, and Cmax vs Tmax separates maximum concentration from its timing. The peak window basics framework provides broader temporal context, while Tmax vs onset distinguishes a PK coordinate from biological onset. The downstream peak effect physiology concept can relate exposure patterns to pharmacodynamic processes without converting the peak window into clinical guidance. The dose response curve and dose PD relationship belong to separate exposure-response layers. Thus, the 25 mg peak window is a PK property of the modeled concentration-time profile, while downstream response interpretation requires separate pharmacodynamic analysis.
Modeling can integrate the entire 25 mg timeline and represent differences in peak magnitude, timing, and shape. Peak window modeling can describe the region around the concentration maximum, while population pharmacokinetics can characterize typical behavior and between-subject variability. Clinical peak data provide observed concentration-time measurements, while peak window summary organizes peak-related temporal features. Food and interaction modifiers may be incorporated through fatty food impact, drug interactions peak, and enzyme inhibitors impact. These factors can influence systemic input, presystemic extraction, or disposition and therefore alter the observed 25 mg profile. The integrated sequence remains: 25 mg input magnitude, absorption, first-pass processing, systemic appearance, distribution, Tmax, and peak window. Each stage has a distinct mechanistic role, allowing the complete profile to be interpreted without turning the input magnitude into dosing advice.
| Timeline Component | Mechanistic Influence | 25 mg Role |
|---|---|---|
| 25 mg input | Defines the modeled magnitude of sildenafil entering the PK system. | Sets the input condition for the profile being interpreted. |
| Absorption | Forms systemic input through gastrointestinal transfer and uptake. | Determines the temporal development of the 25 mg systemic input. |
| First-pass effect | Removes a portion of parent sildenafil before systemic circulation. | Modifies the parent-drug amount available after the 25 mg input. |
| Distribution | Redistributes systemic sildenafil among relevant compartments. | Contributes to the concentration-time shape after systemic appearance. |
| Tmax | Identifies the time coordinate of maximum concentration. | Defines the peak timing for the 25 mg concentration-time profile. |
| Peak window | Represents the temporal region surrounding maximum concentration. | Provides context for the 25 mg profile's peak timing and shape. |
The 25 mg peak window is the PK region surrounding the maximum concentration in a sildenafil concentration-time profile generated from a 25 mg input magnitude. It is a descriptive pharmacokinetic concept rather than a recommended administration interval. The window reflects the concentration curve around its maximum and therefore depends on absorption, systemic input, presystemic metabolism, distribution, and elimination. Its boundaries are not defined solely by the input magnitude because the underlying PK processes determine the shape and timing of the curve. A 25 mg profile can therefore have a characteristic peak region within a particular model while differing from another profile if absorption or disposition parameters change. The concept describes concentration-time behavior only and does not imply a clinical dosing recommendation.
25 mg Tmax is the PK timing coordinate associated with maximum concentration in a sildenafil concentration-time profile generated from a 25 mg input magnitude. It is a time coordinate, not a concentration measure and not a dosing instruction. Tmax emerges from the balance between systemic input and processes that remove or redistribute sildenafil. Absorption timing can influence the rising phase, while distribution and elimination can also affect where the maximum occurs. The exact value therefore depends on the characteristics of the modeled PK profile. It should also be distinguished from biological onset because maximum concentration and onset of a pharmacodynamic process are separate concepts. The term 25 mg Tmax simply specifies the input magnitude used to define the profile being analyzed.
The 25 mg absorption rate describes the mechanistic rate at which systemic input develops from a sildenafil profile using a 25 mg input magnitude. It concerns the temporal formation of systemic input and does not represent therapeutic intensity or clinical response. The rate depends on processes governing gastrointestinal delivery, intestinal transfer, and subsequent availability for systemic appearance. Presystemic metabolism can reduce the amount of parent drug reaching circulation, while distribution and elimination shape the concentration curve after systemic entry. Consequently, absorption rate contributes to the rising portion of the concentration-time profile but does not alone determine Tmax or the peak window. The 25 mg label identifies the modeled input magnitude only. It should not be interpreted as a recommendation about administration or treatment.
The first-pass effect describes presystemic metabolism of absorbed parent sildenafil before it reaches systemic circulation. In a profile using a 25 mg input magnitude, this process can reduce the amount of parent drug available for systemic exposure. The resulting change may influence the maximum concentration and the shape of the concentration-time curve. Its effect on Tmax depends on how presystemic extraction interacts with absorption timing, systemic input, distribution, and elimination. A change in first-pass extraction therefore does not automatically produce a specific shift in peak timing. The 25 mg input establishes the modeled magnitude, while first-pass metabolism determines one component of how much parent drug survives before systemic appearance. The concept remains mechanistic and descriptive rather than clinical.
Food can modify a 25 mg sildenafil concentration-time profile when it changes gastrointestinal delivery, absorption timing, or other PK processes. A food-associated change in gastric transit can alter when sildenafil reaches intestinal absorption sites, which can modify the temporal pattern of systemic input. Depending on the mechanism, the observed peak concentration, Tmax, or broader peak-window shape may change. The effect is not necessarily limited to absorption because presystemic metabolism and later disposition also contribute to the observed profile. Therefore, a food-associated change in the 25 mg peak window should be interpreted from the complete concentration-time curve rather than assigned automatically to a single mechanism. The 25 mg term continues to represent only the modeled input magnitude and does not imply a clinical dosing schedule.
Alcohol can be considered a potential modifier of the 25 mg sildenafil concentration-time profile through effects on gastrointestinal, metabolic, or systemic PK processes. The specific mechanism determines whether the resulting change primarily affects input timing, peak concentration, peak timing, or overall exposure. A change in gastrointestinal conditions can alter the rising phase, while metabolic effects can modify the amount or persistence of parent sildenafil. Because the peak window is an integrated property of the concentration-time curve, several mechanisms can contribute simultaneously. Cmax and Tmax may therefore respond differently to the same modifier. The term 25 mg still refers only to the modeled input magnitude. Alcohol-related PK interpretation remains descriptive and does not provide administration, treatment, or safety guidance.
Enzyme inhibition means reduced activity of a metabolic pathway that may participate in sildenafil metabolism. In a 25 mg input profile, inhibition can change the amount of parent sildenafil surviving presystemic or systemic metabolic processes. This can modify the concentration-time curve and potentially alter peak magnitude. Tmax may also change if the altered metabolic process affects the temporal balance between systemic input and drug removal. However, the direction and size of any change depend on the specific pathway and its contribution relative to absorption, distribution, and other elimination processes. Enzyme inhibition is therefore one mechanistic modifier within the complete PK system. The 25 mg designation identifies the modeled input magnitude and does not change the meaning of the metabolic mechanism.
Enzyme induction refers to increased expression or functional capacity of a metabolic pathway. If the induced pathway contributes to sildenafil metabolism, greater metabolic capacity can alter the amount of parent drug surviving presystemic or systemic metabolism in a 25 mg PK profile. This may change peak concentration and, depending on the timing of input and disposition, may also influence Tmax. The observed result depends on the relative importance of the affected pathway and the other processes governing the concentration-time curve. Enzyme induction therefore should not be interpreted as a direct determinant of a fixed peak-window change. It is one mechanistic factor that can alter systemic exposure. The 25 mg label specifies only the modeled input magnitude and carries no independent clinical recommendation.
Input magnitude can influence the amount of sildenafil appearing in the systemic circulation and therefore can affect the resulting concentration-time profile. A 25 mg input magnitude establishes the quantitative condition being modeled, while the observed peak depends on absorption, presystemic extraction, distribution, metabolism, and elimination. Increasing or decreasing input magnitude can change peak concentration, overall exposure, or other curve characteristics, but the relationship is not necessarily proportional in every PK system. Tmax can remain similar when the temporal shape of input is preserved, or it can change when input and disposition processes interact differently. Dose-related interpretation should therefore focus on the PK relationship between input and observed exposure. The 25 mg designation is used solely as a mechanistic input magnitude, not as dosing advice.
The 25 mg peak window can vary between individuals because the same modeled input magnitude can pass through different physiological and metabolic environments. Differences in gastrointestinal transit, intestinal uptake, metabolic capacity, distribution, and elimination can alter the concentration-time profile. Genetic variation can contribute to differences in metabolic pathways, while age and other biological characteristics can influence relevant PK parameters. These factors may change peak magnitude, Tmax, curve shape, or the width of the surrounding peak region. Consequently, the input magnitude alone does not define an identical peak window for every individual. The term 25 mg identifies the modeled input condition, while the resulting peak window is an emergent property of the complete PK system. Such variability is a descriptive pharmacokinetic phenomenon.
A 25 mg peak window can be modeled by specifying a pharmacokinetic system that represents absorption, systemic input, presystemic extraction, distribution, and elimination. The model generates a concentration-time curve from which the maximum concentration and its associated Tmax can be identified. The surrounding region can then be characterized as the peak window. Different structural models can represent absorption using different input functions and can represent presystemic processes with varying levels of detail. Variability can also be incorporated to describe differences among individuals or simulated profiles. The resulting peak-window estimate depends on model assumptions, parameter values, and the quality of concentration measurements used for estimation. The 25 mg value simply defines the input magnitude used in the modeled scenario.
Population pharmacokinetics can describe 25 mg peak-window behavior by estimating typical PK parameters while representing variability between individuals. A population model can incorporate absorption, presystemic extraction, distribution, and elimination processes and then generate individual concentration-time profiles from which peak concentration and Tmax are derived. Differences among profiles can be summarized statistically rather than assuming one universal peak window. Covariates may explain some variation when supported by appropriate data and model structure. The resulting analysis can therefore distinguish typical 25 mg PK behavior from variability in peak magnitude, timing, or curve shape. Population PK does not change the definitions of the peak window or Tmax. It provides a framework for describing how those PK properties may vary across a population under a common modeled input magnitude.